Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "guselkumab"

FDA Approval Sought for 2 Pediatric Indications for Guselkumab

Michele B. Kaufman, PharmD, BCGP  |  February 11, 2025

The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.

Guselkumab Promising in Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  October 7, 2021

Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).

Guselkumab Promising for Psoriatic Arthritis with Axial Symptoms

Lorraine L. Janeczko  |  July 17, 2021

NEW YORK (Reuters Health)—Guselkumab may be effective in patients who have psoriatic arthritis (PsA) with axial symptoms, a post-hoc analysis of data from two randomized controlled trials suggests.1 “Because PsA is a heterogeneous disease that manifests as various symptoms, treatment choices should involve consideration of all relevant domains of disease for each individual patient,” researchers…

Guselkumab Approved for PsA

Michele B. Kaufman, PharmD, BCGP  |  August 6, 2020

Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…

FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis

Natasha Yetman  |  July 15, 2020

HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…

MicroOne / shutterstock.com

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  May 17, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Study Results for 9 New Psoriatic Arthritis Drugs

Thomas R. Collins  |  June 21, 2018

CHICAGO—As Eric Ruderman, MD, professor of medicine in rheumatology at Northwestern University Feinberg School of Medicine in Chicago, began his talk on psoriatic arthritis treatment at the ACR State-of-the-Art Clinical Symposium in April, he marveled a bit at how much there was to cover. Drugs gaining prominence in the treatment of rheumatoid arthritis and dermatological…

Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles

Marilynn Larkin  |  May 29, 2018

NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…

International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 30, 2018

In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences